newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives

LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 LP659 Phase 1 initiation of first in-human clinical study on